protein tyrosine phosphatase receptor type EGenealiases: HPTPE · PTPE · R-PTP-EPSILON
Q-omics provides the consensus-scored PTPRE profile across patient tissues and cancer cell-line models. PTPRE expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPRE is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PTPRE RNA expression shows 19,900 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where PTPRE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRE survival associations across molecular data types. PTPRE RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRE RNA expression–survival associations across cancer types. High PTPRE expression shows unfavorable associations in ACC, UVM and CESC, but favorable associations in SKCM, BRCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPRE RNA expression.
This table summarizes PTPRE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRE shows lower tumor expression in LUSC and higher tumor expression in KIRC, THCA, HNSC, KIRP and STAD. The KIRC box plot shows higher PTPRE RNA expression in tumor versus normal tissue (log2 FC = +1.654, t-test p < 0.001).
This table shows molecular features associated with PTPRE in patient tissues and cancer cell lines. In patient samples, PTPRE shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
